MAB2476

antibody from R&D Systems

Targeting: BRCA2 BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11

Western blot (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

MAB2476

Provider

R&D Systems

Product name

Human BRCA2 Antibody

Antibody type

Monoclonal

Description

Protein A or G purified from hybridoma culture supernatant. Detects endogenous human BRCA2.

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Antigen sequence

P51587


Isotype

IgG

Antibody clone number

234403

Vial size

100 ug

Concentration

LYOPH

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

References

Submitted references

FoxM1-dependent RAD51 and BRCA2 signaling protects idiopathic pulmonary fibrosis fibroblasts from radiation-induced cell death.

Im J, Lawrence J, Seelig D, Nho RS
Cell death & disease 2018 May 22;9(6):584

---

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T
The Journal of clinical investigation 2017 Jun 1;127(6):2392-2406

---

IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.

Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan-Reed K, Langer SK, Nejati R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, Skorski T
Molecular cancer research : MCR 2017 Aug;15(8):967-972

---

Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines.

Ishiguro K, Zhu YL, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES
Journal of translational science 2016;2(2):117-124

---

RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis.

Yang G, Mercado-Uribe I, Multani AS, Sen S, Shih IeM, Wong KK, Gershenson DM, Liu J
International journal of cancer 2013 Jul 15;133(2):275-85

---

Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.

Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jun 15;16(12):3171-81

Western blot

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

Detection of Human BRCA2 by Western Blot. Western blot shows lysates of Capan-1 human pancreatic adenocarcinoma cell line, HeLa human cervical epithelial carcinoma cell line, and U2OS human osteosarcoma cell line. PVDF membrane was probed with 0.2 µg/mL of Human BRCA2 Monoclonal Antibody (Catalog # MAB2476) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for BRCA2 at approximately 380 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.